Maegim한국어

에스티팜

237690KOSDAQSector: Pharma & Biotech
₩114,000▲ 0.09%Market cap ₩2.38TAs of Jul 21, 2026 close · updated once daily
A
Grade A66.3 ptsTop 19% of 2,523 stocks
Financial strength
75.6
Growth momentum
80.6
Price attractiveness
45.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

75.6
How much debt does it carry relative to equity?
Debt-to-equity ratio
32.0%
✓ Above median · Top 30.3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
226.2%
✓ Above median · Top 42.5% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
16.6%
✓ Above median · Top 10.1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
9.3%
✓ Above median · Top 14.8% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

80.6
How much did revenue grow in a year?
Revenue growth (YoY)
21.2%
✓ Above median · Top 23.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
10.0%
✓ Above median · Top 33.2% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
98.4%
✓ Above median · Top 13.6% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
207.7%
✓ Above median · Top 7.8% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

45.5
Is the price expensive relative to earnings?
P/E (price-to-earnings)
43.3x
✓ Above median · Top 35.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
4.01x
✗ Below median · Top 73.8% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15